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lation (AF). It is therefore relevant to evaluate NOACs relative cost-effectiveness 
in Portuguese AF patients. Methods: A Markov model was used to analyze the 
disease progression over a lifetime horizon. Relative efficacy data for stroke 
(ischemic and hemorrhagic), bleeding (intracranial, other major bleeds and clini-
cally relevant non-major bleeds), myocardial infarction and treatment discontinu-
ation were used by means of pairwise indirect treatment comparisons between 
apixaban, dabigatran and rivaroxaban using warfarin as a common comparator. 
Resource use was obtained from Diagnosis Related Group legislation data base and 
an expert panel. Model outputs included life years gained, quality-adjusted life 
years (QALYs), direct healthcare costs and incremental cost-effectiveness ratios 
(ICERs). Results: Apixaban provided the highest life years gained and QALYs. The 
apixaban ICER versus warfarin and dabigatran was 5,529€ /QALY and 9,163€ /QALY, 
respectively. Apixaban was dominant versus rivaroxaban (higher health gains and 
lower costs). Results were robust over a wide range of inputs in sensitivity analy-
ses. Apixaban had a 70% chance of being cost-effective (at a threshold of 20,000€ /
QALY) versus the set of all other therapeutic options. ConClusions: Apixaban 
is a cost-effective alternative to warfarin and dabigatran and is dominant versus 
rivaroxaban in AF patients from a Portuguese national healthcare system perspec-
tive. These conclusions are based on indirect treatment comparisons. Despite 
this limitation, this information is relevant for different health care decision 
makers.
PCV113
Dabigatran For the treatment anD SeConDary PreVention oF VenouS 
thromboemboliSm
Stevanovic J1, Kappelhoff B2, Voorhaar M3, Postma MJ1
1University of Groningen, Groningen, The Netherlands, 2Boehringer Ingelheim GmbH, Ingelheim, 
Germany, 3Boehringer Ingelheim, Alkmaar, The Netherlands
objeCtives: Dabigatran was proven to have similar effect on the recurrence of 
venous thromboembolism (VTE) and a lower risk of bleeding compared to vita-
min K antagonists (VKAs). This study aims to assess the cost-effectiveness (CE) 
of dabigatran for the treatment and secondary prevention in high risk patients 
of VTE compared to VKAs in the Dutch setting. Methods: Previously published 
Markov model was modified and updated to assess the CE of dabigatran and VKAs 
for the treatment and secondary prevention in high risk patients of VTE from a 
societal perspective in the base-case analysis. The model was populated with 
efficacy and safety data from major dabigatran trials (i.e. RE-COVER, RECOVER II, 
RE-MEDY and RE-SONATE), Dutch specific costs, and utilities derived from dabi-
gatran trials or other published literature. Univariate, probabilistic sensitivity 
and a number of scenario analyses on the impact of various decision-analytic 
settings (e.g. the perspective of analysis, use of anticoagulants only for treat-
ment or only for secondary prevention) were tested on the incremental cost-
effectiveness ratio (ICER). Results: In the base-case, patients on dabigatran 
gained an additional 0.583 discounted quality adjusted life years (QALYs) over 
a lifetime and savings of € 1,996. Results of univariate sensitivity analysis were 
quite robust. The probability that dabigatran is cost-effective at a willingness-
to-pay threshold of € 20,000/QALY was 100%. Except for the scenario comparing 
dabigatran to VKAs from the healthcare provider perspective and the one com-
paring dabigatran to placebo for the prevention of recurrent VTE in patients who 
are at equipoise for anticoagulation treatment where the ICERs for dabigatran 
compared to VKAs of € 1,005 and € 33,305 per QALY gained, respectively were esti-
mated, other scenarios showed dabigatran was cost-saving. ConClusions: From 
a societal perspective, dabigatran is likely to be a cost-effective or even cost-saving 
strategy for treatment and secondary prevention of VTE compared to VKAs in the 
Netherlands.
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objeCtives: To estimate the health benefits and cost-effectiveness of a polypill 
intervention (100mg aspirin, 20mg atorvastatin and 10mg ramipril) for the second-
ary prevention of cardiovascular (CV) events in adults with a history of myocardial 
infarction (MI) from the perspective of the Spanish health system compared with 
multiple monotherapy. Methods: A Markov model was developed to estimate 
health outcomes, costs and incremental cost-effectiveness ratio (ICER) per LY 
gained and per QALY gained using a 10-year time horizon. The patient population 
included were men and women with an average age of 64.7 years, a history of 
MI and an indication for secondary prevention treatment. Patients in the model 
have a 3-month probability cycle to have one of the following five CV events: acute 
coronary syndrome, non-fatal stroke, non-fatal congestive heart failure requir-
ing hospitalization, unplanned revascularization procedures, or (non-)CV death. 
Model inputs on efficacy, utility and adherence were obtained from systematic 
reviews. Different scenarios were modelled using different sources for acute event 
costs and alternative prices for polypill and its monocomponents. Probabilistic 
analyses were performed to test the robustness of the results. Results: Polypill 
showed to prevent 45 CV fatal and non-fatal events per 1,000 patients in Spain 
in the base case. Total LYs and QALYs gained were 38 and 36 respectively, show-
ing polypill was the dominant strategy. Probabilistic sensitivity analyses for the 
base-case assumptions showed a 90.1% chance of the polypill being cost-effec-
tive at a willingness-to-pay threshold of € 30,000 per QALY gained compared with 
multiple monotherapy. Alternative scenario analyses showed that the polyp-
ill resulted to be dominant or cost-effective in all scenarios. ConClusions: 
The polypill intervention appears to be the dominant or cost-effective strategy 
versus its monocomponents taken separately, showing it can prevent fatal and 
non-fatal CV events in the Spanish population as well as to reduce healthcare 
costs.
A pharmacoeconomic model of administering actovegin in female patients with 
chronic venous disease of lower extremities was developed on the basis of clini-
cal data (Uchkin IG et al.). Three strategies of complex therapy were considered in 
three groups of 100 patients each: 1st group — standard management, 2nd group 
— standard management + local actovegin, 3rd group — standard management + 
both intravenous and local actovegin. Criteria of efficiency were defined as removal 
of heavy legs syndrome and wound healing. Costs of drug administration, hospi-
talization and lab tests were under consideration. The time horizon equalled 1 
month. Results: We determined costs of patient management for each of the 
groups. The costs constituted 8 732 092,50 RUB in the 1st group, 8 543 937,88 RUB in 
the 2nd group, and 8 860 710,75 RUB in the 3rd group, so they did not vary consider-
ably. The cost effectiveness for the removal of heavy legs syndrome in the standard 
therapy group was equal to 14 895,97, while it constituted 10 744,87 and 11 826,97 
in the second and third groups, respectively. CER values considering the number 
of patients with wound healing were 39 482,20 for the 1st group, and 26 889,65 and 
15 689,74 for the 2nd and 3rd groups, respectively. ConClusions: Actovegin in 
complex therapy of complicated chronic venous disease of lower extremities is 
substantiated from the pharmacoeconomic standpoint of cost effectiveness ratio.
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objeCtives: Acute coronary syndrome is a “vehicle diagnosis”, the ambulance 
service and involves unstable angina, myocardial infarction, including – without 
segment elevation of ST segment. Aim of this study was to conduct clinical and 
economic analysis of application of fondaparinux sodium and enoxaparin sodium 
in the treatment of acute coronary syndrome. Methods: The method of modeling 
with decision-tree model and “cost-effectiveness” ratio were used. Endpoints were: 
mortality, the onset of myocardial infarction in the 9th, 30th and 180th day from 
the start of the study regarding the side effects in patients with acute coronary 
syndrome based on the results of clinical trials OASIS-5. Calculating the cost of drugs 
and medical services was conducted according to experts and standard of medi-
cal care. Results: The cost of treatment of a single patient with acute coronary 
syndrome with fondaparinux sodium were lower compared with enoxaparin 
sodium to 9th, 30th and 180th day of treatment at 38 € , 42 € and 36 € , respectively. 
The cost-effectiveness ratio on the criterion of “the likelihood of myocardial infarc-
tion” for fondaparinux and enoxaparin on the 9th day of treatment was 5210 € and 
6641 € , on the 30th day - 4084 € and 4810 € , on the 180th day - 3396 € and 3939 € , 
respectively. The cost-effectiveness ratio on the criterion “probability of death” for 
fondaparinux and enoxaparin on the 9th day of treatment was 7525 € and 9088 € , 
on the 30th day - 5351 € and 5635 € , on the 180th day - 3839 € and 4171 € , respec-
tively. ConClusions: The use of fondaparinux sodium is the dominant technology 
in myocardial infarction without lifting ST segment, other direct anticoagulants are 
assigned only in case of its absence.
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objeCtives: Patients eligible for bariatric surgery in Germany often do not receive 
this treatment, and sometimes receive no medical care for their obesity at all as 
the conventional care (CC) of behaviour/activity programmes are not reimbursed 
by the sickness funds. Methods: We developed a Markov model to estimate the 
long-term (20 year) outcomes and costs for patients who receive bariatric surgery 
(gastric bypass or sleeve gastrectomy), CC, or no care (NC), from a German health-
care perspective. Body mass index (BMI) change, type II diabetes mellitus (T2DM), 
stroke, myocardial infarction and cancer were all included; inputs for these were 
taken from recent network meta-analyses. Utilities and costs were sourced from 
the literature and the German DRG tariff. It was assumed that NC patients had 
no obesity care costs and remained at baseline BMI, blood pressure and choles-
terol level. The populations considered were patients with BMI≥ 40 or BMI≥ 35 with 
obesity-related comorbidities, and the subpopulation of T2DM patients. Costs and 
outcomes were discounted at 3% yearly. Results: Compared to those receiving CC 
and NC, patients undergoing bariatric surgery were found to live longer and have 
fewer cases of stroke (-11 and -9 cases per 1000 patients, respectively), myocardial 
infarction (-35 and -41 cases per 1000 patients, respectively) and cancer (-17 cases 
per 1000 patients for both). The difference between bariatric surgery patients and 
CC or NC was even greater in patients with T2DM. Bariatric surgery was found to 
have an ICER of € 361 per QALY versus CC (incremental cost € 921, QALY gain 2.55) 
and of € 812 per QALY versus NC (incremental cost € 2055, QALY gain 2.53). Bariatric 
surgery was associated with an ICER of less than € 10,000/QALY in 100% of simula-
tions versus both CC and NC. ConClusions: Bariatric surgery improves patient 
outcomes and is cost-effective in Germany compared to conventional or no care.
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objeCtives: Recently, three novel non-vitamin K antagonist oral anticoagulants 
(NOACs) got reimbursed in Portugal for patients with non-valvular atrial fibril-
